Tue, Dec 23, 2014, 12:09 AM EST - U.S. Markets open in 9 hrs 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Response Genetics, Inc Message Board

  • culleraa culleraa Nov 13, 2012 6:47 AM Flag

    RGDX survival confirmed

    For now. I guess the 500k from GSK is in the revenues, so those and the gm are really lower. Also the gain in dx revenues was same order of magnitude as decline last time .. was it 150K ... which was said to be slight, so this is a slight+? gain . Net +- not much. Right direction though.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • what?

      Total revenues for the quarter ended September 30, 2012 increased to $5.40 million, compared to $3.84 million for the quarter ended June 30, 2012 and $5.10 million for the quarter ended September 30, 2011. The Company's pharmaceutical client revenue increased by $1.37 million and the ResponseDX® revenue increased by $189 thousand relative to the quarter ended June 30, 2012.

      "We are very pleased with the financial results for the quarter ended September 30, 2012, which improved again relative to the prior quarter. Since the fourth quarter of last year, we continued to realize consecutive quarter-over-quarter positive results from the many changes implemented by the Company. Gross margins have increased nearly two-fold from the fourth quarter of last year, and operating loss has continued to decrease significantly, or nearly two-fold, since last quarter and by a factor of nearly 2.8 from the fourth quarter of last year," said Thomas Bologna, the Company's Chairman & Chief Executive Officer.

      The Company's cash position increased substantially to $10.8 million at September 30, 2012 compared to $2.6 million at June 30, 2012.

      Mr. Bologna concluded, "In the third quarter we also increased our cash position significantly to nearly $11,000,000. Today we have a strong balance sheet coupled with steady and consecutive quarter-over-quarter financial performance. Going forward, we believe we are well positioned, both strategically and financially, to continue building a strong organization to capitalize on the promise of personalized medicine."

      I think you need to concentrate more on what I posted as real +++ CATS and the reason LT raised the Sentiment from Neutral to BUY!

      I see RGDX trading at $2 by end of year!

      $3 next spring when we see the Dx sales ramping too...maybe GSK just BUYS em up too, they own 15% now!

      Frank

    • Sorry. I am new to this stock. Could you be more precise?
      Thanks

 
RGDX
0.40-0.0300(-6.98%)Dec 22 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NASDAQMon, Dec 22, 2014 4:00 PM EST
Rite Aid Corporation
NYSEMon, Dec 22, 2014 4:01 PM EST